JeanMarie Guenot: What You Should Know About Her Historic Career

JeanMarie Guenot is one of the most outstanding American entrepreneurs today. She is a motivation both to the male and female folks. With over 20 years doing the seemly impossible, no one is in doubt of her entrepreneurial qualities. She has worked for others and grew their companies to enviable height on guenotllc.com. This did not stop her from founding and building her own companies into a force to be reckoned with. For instance, she founded SKS Ocular and spent quality time building it before relinquishing its leadership to someone else. These are some of the few reasons why most companies will go to any length to get her service.

Amphivena Therapeutics, Inc. is undoubtedly fortunate to have this industrial giant as President and CEO. According to amphivena.com, The company is sure to scale heights and already the results have been coming in. Amphivena Therapeutics is no mean company as it always deliver the best, which is the reason it only settles for the best of hands. Amphivena is a preclinical stage company based in San Francisco, California. Here is a company with the lofty mission of eradicating blood cancers by discovering new and effective therapies that works in conjunction with the human immune system for the complete extermination of tumor cells and all that aid their growth. In a nutshell, the company is out to restore the flow of life.

JeanMarie Guenot has worked in virtually all departments available in the industry. There is no capacity you put her that will not perform. When it comes to Pharmaceutical R &D, she has an edge; in Corporate & Commercial Development, she is never a push-away; in Project &Alliance Management, her wealth of experience counts; in Venture Capital, she understands its complexity. She has brought a number of companies from a state of collapse to the acme of the industry.

JeanMarie Guenot specializes on therapies that address autoimmune diseases, oncology, cardiovascular diseases, neurology and ophthalmic diseases. She is a PhD and MBA holder from the University of California, San Francisco and The Wharton School at the University of Pennsylvania respectively.

Read more: Maverick Therapeutics and Takeda Announce Five-year Collaboration to Advance T-Cell Engagement Therapies

Leave a Reply